A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Varegacestat in Participants With or Without Hepatic Impairment
Latest Information Update: 24 Oct 2025
At a glance
- Drugs Varegacestat (Primary)
- Indications Fibroma
- Focus Pharmacokinetics
- Sponsors Immunome
Most Recent Events
- 17 Oct 2025 Status changed from recruiting to active, no longer recruiting.
- 10 Mar 2025 Status changed from not yet recruiting to recruiting.
- 28 Feb 2025 New trial record